Filing Details
- Accession Number:
- 0001209191-19-059404
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-05 21:35:20
- Reporting Period:
- 2019-12-03
- Accepted Time:
- 2019-12-05 21:35:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 353569 | Quidel Corp | QDEL | In Vitro & In Vivo Diagnostic Substances (2835) | 942573850 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1609320 | Werner Kroll | 9975 Summers Ridge Road San Diego CA 92121 | Svp, R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-12-03 | 3,357 | $68.03 | 16,769 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-12-03 | 6,620 | $22.85 | 23,389 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-03 | 6,620 | $68.01 | 16,769 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-03 | 12,974 | $68.02 | 3,795 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Options | Disposition | 2019-12-03 | 6,620 | $0.00 | 6,620 | $22.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-05-27 | No | 4 | M | Direct |
Footnotes
- The weighted average sale price for these transactions was $68.028508 per share, with a range of $67.95 to $68.10. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
- The amount of securities beneficially owned following this transaction include an additional 357 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan.
- The weighted average sale price for these transactions was $68.010509 per share, with a range of $67.95 to $68.12. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
- The weighted average sale price for these transactions was $66.018852 per share, with a range of $67.95 to $68.12. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
- 13,242 shares vested on the second anniversary date of the grant date, May 27, 2016. 6,621 shares vested on the third anniversary date of the grant date, May 27, 2017. 6,620 shares vested on the fourth anniversary date of the grant date, May 27, 2018.
Billionaire Hedge Funds
